决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Impact of HPV status on immune responses in head and neck squamous cell carcinoma.
从HPV+和HPV- HNSCC扩增的TIL群体显示出相似的IFN-反应性。
我们研究的主要目的是了解免疫细胞组成以及TIL(肿瘤浸润淋巴细胞)的肿瘤反应性在HPV阳性(HPV+)和HPV阴性(HPV-)头颈部鳞状细胞癌(HNSCC)中的影响。从原发性HNSCC肿瘤中建立TIL培养物,使用流式细胞术对T细胞亚群进行表型表征,并使用干扰素(IFN)-ELISA测定法确定TIL功能。使用NanoString Immune Profiler按HPV状态确定免疫特征,并使用多重免疫组织化学(MIHC)量化免疫细胞分布及其空间关系。结果显示,HPV+和HPV-HNSCC具有相似的扩增IFN反应性TIL群体的能力,且这些TIL群体具有相似的特征。NanoString分析显示,HPV+HNSCC中与B细胞功能相关的基因差异表达增加,在Benjamini-Yekutieli校正p值<0.001时具有显著性。MIHC还显示,与HPV-HNSCC相比,HPV+HNSCC肿瘤区域中CD8+T细胞和CD19/CD20+B细胞密度增加(p<0.01)。肿瘤B细胞含量和基质浆细胞含量的联合指标增加与接受免疫检查点抑制剂治疗的HPV-HNSCC患者的无进展生存期延长相关(p=0.03)。总之,从HPV+和HPV-HNSCC扩增的TIL群体显示出相似的IFN反应性。然而,我们在HPV+HNSCC中鉴定出强烈的B细胞特征,并且较高的B细胞和浆细胞含量与接受免疫检查点抑制剂治疗的HPV-HNSCC患者改善的PFS相关。
The main objective of our study was to understand the impact of immune cell composition and the tumor-reactivity of tumor infiltrating lymphocytes (TIL) in HPV-positive (HPV + ) and HPV-negative (HPV - ) head and neck squamous cell carcinoma (HNSCC). TIL cultures were established from primary HNSCC tumors, the T cell subsets were phenotypically characterized using flow cytometry, and Interferon (IFN)- ELISA assay was used to determine TIL function. NanoString Immune Profiler was used to determine an immune signature by HPV-status, and multiplex immunohistochemistry (MIHC) was used to quantify immune cell distributions and their spatial relationships. Results showed that HPV + and HPV - HNSCC had similar capacity to expand IFN- reactive TIL populations, and these TIL populations had similar characteristics. NanoString analysis revealed increased differential expression of genes related to B cell functions in HPV + HNSCC, which were significant at a Benjamini-Yekutieli adjusted p-value of < 0.001. MIHC also displayed increased CD8 + T cell and CD19/CD20 + B cell densities in the tumor region of HPV + HNSCC as opposed to HPV - HNSCC (p < 0.01). Increases in a combined metric of tumor B cell content and stromal plasma cell content was associated with increased progression-free survival in HPV - HNSCC patients treated with immune checkpoint inhibitor therapy (p = 0.03). In summary, TIL populations expanded from HPV + and HPV - HNSCC displayed similar IFN- reactivity. However, we identified a strong B-cell signature present within HPV + HNSCC, and higher B and plasma cell content associated with improved PFS in HPV - HNSCC patients treated with immune checkpoint inhibitors.
MEMBER ACCOUNT
登录成功会直接打开下一页。